Skye Bioscience

Clinical-stage biotechnology company developing next-generation therapeutics for obesity and other metabolic diseases

Biotech & Life Sciences

Sector

Clinical-stage biopharmaceutical company

Model

01Company Overview

Clinical-stage biotechnology company developing next-generation therapeutics for obesity and other metabolic diseases. Its lead candidate, nimacimab, is a peripherally restricted monoclonal antibody that inhibits CB1 receptors and is being evaluated alone and in combination with GLP-1 therapies to improve fat loss and metabolic health.

02Backed By1 investor

5V5AM Ventures→

03Recent Activity

Is this your company? Claim your profile

FROM 5AM Ventures

5AM Ventures participated in a $68M PIPE financing as part of the Skye Bioscience/Redx Pharma transaction agreement, alongside Abingworth, British Business Bank, and NEXTBio Capital. The combined company will operate as Fibrx Therapeutics.